{
    "2018-05-23": [
        [
            {
                "time": "2018-03-15",
                "original_text": "J&J hit with $21.7 million verdict in another talc asbestos cancer case",
                "features": {
                    "keywords": [
                        "J&J",
                        "verdict",
                        "talc",
                        "asbestos",
                        "cancer"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-05",
                "original_text": "J&J Loses Second Talc-Asbestos Trial and Damages May Grow",
                "features": {
                    "keywords": [
                        "J&J",
                        "trial",
                        "damages",
                        "talc",
                        "asbestos"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-05-10",
                "original_text": "Why Geron Corporation Stock Is Heating Up",
                "features": {
                    "keywords": [
                        "Geron Corporation",
                        "stock",
                        "heating up"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-06-20",
                "original_text": "Should PowerShares Dividend Achievers Portfolio (PFM) Be on Your Investing Radar?",
                "features": {
                    "keywords": [
                        "PowerShares",
                        "Dividend Achievers",
                        "Portfolio",
                        "PFM"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "dividends"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-15",
                "original_text": "Is Fidelity Dividend ETF for Rising Rates (FDRR) a Hot ETF Right Now?",
                "features": {
                    "keywords": [
                        "Fidelity",
                        "Dividend ETF",
                        "Rising Rates",
                        "FDRR"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "ETFs",
                        "dividends"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-25",
                "original_text": "Eli Lilly Gets FDA Approval for Taltz in Genital Psoriasis",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "FDA",
                        "approval",
                        "Taltz",
                        "psoriasis"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-09-10",
                "original_text": "Why the world needs more than one Ebola vaccine",
                "features": {
                    "keywords": [
                        "Ebola",
                        "vaccine",
                        "world",
                        "needs"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-05",
                "original_text": "Merckâ€™s experimental and unlicensed Ebola vaccine is being used in latest outbreak",
                "features": {
                    "keywords": [
                        "Merck",
                        "experimental",
                        "unlicensed",
                        "Ebola",
                        "vaccine",
                        "outbreak"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-11-20",
                "original_text": "Is This Stock the Next Biotech Acquisition Target?",
                "features": {
                    "keywords": [
                        "Stock",
                        "Biotech",
                        "Acquisition",
                        "Target"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}